The safety and efficacy of autologous peripheral blood mononuclear cell ex vivo culture amplified cells (MNC-QQ) for alopecia: Phase 1 / 2 clinical study

Phase 1

Recruiting

• Conditions: Alopecia; Hair loss, alopecia, baldness

• Registration Number: JPRN-jRCTb030230286
• Lead Sponsor: Ikeda Yoshio

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-08-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

1. Patients with written informed consent.
2. Patiens are at the age of 18 to 75 at the time of informed consent.
3. Patients affected alopecia and want to receive regenerative therapy.

Exclusion Criteria

1. Patients with HbA1c(NGSP) more than 10.0 with the medication for diabetes.
2. Patients with systemic infection.
3. Patients with severe anemia.
4. Patients with malignancy, or within 5 years after recover from malignant tumor (10 years after breast cancer), except for cutaneous basal cell carcinoma.
5. Patients with hematopoietic disorders such as leukemia, myeloproliferative disease, marrow dysplasia syndrome.
6. Pregnant women.
7. Patients infected with HIV, active HBV, HCV, HTLV, or syphilis in screening test.
8. Patients not expect to live for a year or more.
9. Patients enrolled in any other clinical trial within 90 days before informed consent.
10. Patients who can't consent not to change medication.
11. Any other reason that the Clinical Researchers may have for considering a case unsuitable for the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified